vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and MAXLINEAR, INC (MXL). Click either name above to swap in a different company.
ACADIA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($268.1M vs $137.2M, roughly 2.0× MAXLINEAR, INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 1.4% vs -32.9%, a 34.3% gap on every dollar of revenue. On growth, MAXLINEAR, INC posted the faster year-over-year revenue change (43.0% vs 9.7%). Over the past eight quarters, MAXLINEAR, INC's revenue compounded faster (22.1% CAGR vs 5.3%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
MaxLinear, Inc. is an American electronic hardware company. Founded in 2003, it provides highly integrated radio-frequency (RF) analog and mixed-signal semiconductor products for broadband communications applications. It is a New York Stock Exchange-traded company.
ACAD vs MXL — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $268.1M | $137.2M |
| Net Profit | $3.6M | $-45.1M |
| Gross Margin | — | 57.5% |
| Operating Margin | -1.7% | 30.0% |
| Net Margin | 1.4% | -32.9% |
| Revenue YoY | 9.7% | 43.0% |
| Net Profit YoY | — | -203.0% |
| EPS (diluted) | $0.02 | $-0.52 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $268.1M | $137.2M | ||
| Q4 25 | $284.0M | $136.4M | ||
| Q3 25 | $278.6M | $126.5M | ||
| Q2 25 | $264.6M | $108.8M | ||
| Q1 25 | $244.3M | $95.9M | ||
| Q4 24 | $259.6M | $92.2M | ||
| Q3 24 | $250.4M | $81.1M | ||
| Q2 24 | $242.0M | $92.0M |
| Q1 26 | $3.6M | $-45.1M | ||
| Q4 25 | $273.6M | $-14.9M | ||
| Q3 25 | $71.8M | $-45.5M | ||
| Q2 25 | $26.7M | $-26.6M | ||
| Q1 25 | $19.0M | $-49.7M | ||
| Q4 24 | $143.7M | $-57.8M | ||
| Q3 24 | $32.8M | $-75.8M | ||
| Q2 24 | $33.4M | $-39.3M |
| Q1 26 | — | 57.5% | ||
| Q4 25 | 90.8% | 57.6% | ||
| Q3 25 | 92.2% | 56.9% | ||
| Q2 25 | 92.2% | 56.5% | ||
| Q1 25 | 91.7% | 56.1% | ||
| Q4 24 | 91.6% | 55.6% | ||
| Q3 24 | 92.5% | 54.4% | ||
| Q2 24 | 92.5% | 54.6% |
| Q1 26 | -1.7% | 30.0% | ||
| Q4 25 | 6.1% | -10.9% | ||
| Q3 25 | 12.8% | -32.7% | ||
| Q2 25 | 12.2% | -22.6% | ||
| Q1 25 | 7.9% | -48.0% | ||
| Q4 24 | 59.1% | -44.7% | ||
| Q3 24 | 12.6% | -82.3% | ||
| Q2 24 | 12.6% | -44.4% |
| Q1 26 | 1.4% | -32.9% | ||
| Q4 25 | 96.3% | -10.9% | ||
| Q3 25 | 25.8% | -36.0% | ||
| Q2 25 | 10.1% | -24.4% | ||
| Q1 25 | 7.8% | -51.8% | ||
| Q4 24 | 55.4% | -62.8% | ||
| Q3 24 | 13.1% | -93.4% | ||
| Q2 24 | 13.8% | -42.7% |
| Q1 26 | $0.02 | $-0.52 | ||
| Q4 25 | $1.61 | $-0.17 | ||
| Q3 25 | $0.42 | $-0.52 | ||
| Q2 25 | $0.16 | $-0.31 | ||
| Q1 25 | $0.11 | $-0.58 | ||
| Q4 24 | $0.86 | $-0.68 | ||
| Q3 24 | $0.20 | $-0.90 | ||
| Q2 24 | $0.20 | $-0.47 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $61.1M |
| Total DebtLower is stronger | — | $123.8M |
| Stockholders' EquityBook value | — | $454.2M |
| Total Assets | $1.6B | $771.3M |
| Debt / EquityLower = less leverage | — | 0.27× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $61.1M | ||
| Q4 25 | $177.7M | $72.8M | ||
| Q3 25 | $258.0M | $111.9M | ||
| Q2 25 | $253.6M | $108.6M | ||
| Q1 25 | $217.7M | $102.8M | ||
| Q4 24 | $319.6M | $118.6M | ||
| Q3 24 | $155.1M | $148.5M | ||
| Q2 24 | $177.1M | $185.1M |
| Q1 26 | — | $123.8M | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $454.2M | ||
| Q4 25 | $1.2B | $451.9M | ||
| Q3 25 | $917.3M | $464.7M | ||
| Q2 25 | $822.4M | $488.3M | ||
| Q1 25 | $765.2M | $493.2M | ||
| Q4 24 | $732.8M | $516.3M | ||
| Q3 24 | $577.2M | $556.9M | ||
| Q2 24 | $516.7M | $617.3M |
| Q1 26 | $1.6B | $771.3M | ||
| Q4 25 | $1.6B | $796.4M | ||
| Q3 25 | $1.3B | $808.1M | ||
| Q2 25 | $1.2B | $863.7M | ||
| Q1 25 | $1.1B | $855.3M | ||
| Q4 24 | $1.2B | $864.6M | ||
| Q3 24 | $976.9M | $895.3M | ||
| Q2 24 | $914.1M | $973.2M |
| Q1 26 | — | 0.27× | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
